The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
暂无分享,去创建一个
J. Hewitt | A. Verduri | A. Vilches-Moraga | L. Pearce | M. Stechman | R. Short | A. Price | J. Collins | E. Bruce | A. Einarsson | F. Rickard | J. Hesford | F. Barlow-Pay | K. McCarthy | Terence J Quinn | Enrico Clini | Philip Braude | S. Moug | Ben Carter | Emma Mitchell | Mark Holloway | E. Clini | P. Myint | P. Braude | Phyo K. Myint
[1] J. Hewitt,et al. Study protocol for the COPE study: COVID-19 in Older PEople: the influence of frailty and multimorbidity on survival. A multicentre, European observational study , 2020, BMJ Open.
[2] J. Hewitt,et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study , 2020, The Lancet Public Health.
[3] L. Mantovani,et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis , 2020, Heart.
[4] P. Serruys,et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.
[5] P. Ponikowski,et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors , 2020, European heart journal.
[6] A. Troxel,et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 , 2020, The New England journal of medicine.
[7] G. Mancia,et al. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.
[8] Virendrasinh Ravat,et al. A Systematic Review of Cases of Acute Respiratory Distress Syndrome in the Coronavirus Disease 2019 Pandemic , 2020, Cureus.
[9] Qingbo Xu,et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.
[10] A. Pickles,et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust , 2020, medRxiv.
[11] J. Aronson,et al. Drugs and the renin-angiotensin system in covid-19 , 2020, BMJ.
[12] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.
[13] Ke Ma,et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.
[14] W. Gong,et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.
[15] O. Pfister,et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? , 2020, European heart journal.
[16] Michael Roth,et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.
[17] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[18] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[19] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[20] Ahmed A. Alani,et al. Association between preadmission frailty and care level at discharge in older adults undergoing emergency laparotomy , 2020, The British journal of surgery.
[21] M. Narukawa,et al. Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon , 2019, PloS one.
[22] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[23] J. S. Cohen,et al. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference. , 2001, Archives of internal medicine.
[24] J. Pogue,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.
[25] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.